



## **ANTARES PHARMA TO PRESENT AT THE OPPENHEIMER 22<sup>nd</sup> ANNUAL HEALTHCARE CONFERENCE**

**EWING, NJ (December 12, 2011)** -- Antares Pharma, Inc. (NYSE Amex: AIS), today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer will present at the Oppenheimer 22<sup>nd</sup> Annual Healthcare Conference on Wednesday, December 14, 2011 at 10:50 a.m. ET (Eastern Time). A live webcast of the presentation will be available at <http://www.veracast.com/webcasts/opco/healthcare2011/08207344.cfm>. The webcast will automatically be archived approximately three hours after the live event and will be available for 90 days through March 13<sup>th</sup>, 2012.

### **About Antares Pharma**

Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company's subcutaneous and intramuscular injection technology platforms include VIBEX™ disposable pressure-assisted auto injectors, disposable multi-use pen injectors and Vision™ reusable needle-free injectors distributed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. In the injector area, Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH) and a partnership with Ferring that includes Zomacton® hGH. In the gel-based area, the Company's FDA approved product is Anturool® gel, an oxybutynin ATD™ gel for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for the U.S. and Canada. Antares' partnership with BioSante includes LibiGel® transdermal testosterone gel in Phase 3 clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin® estradiol gel indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma has two facilities in the U.S. The Parenteral Products Division located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company's reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company's corporate offices and Pharma Division are located in Ewing, New Jersey, where pharmaceutical products are developed utilizing both the Company's transdermal systems and drug/device combination products.

### **Contacts:**

#### **Antares Pharma, Inc.**

Robert F. Apple  
Chief Financial Officer  
(609) 359-3020

### **Investors:**

#### **Westwicke Partners, LLC**

John Woolford  
(443) 213-0506  
[john.woolford@westwicke.com](mailto:john.woolford@westwicke.com)

### **Media:**

#### **Tiberend Strategic Advisors, Inc.**

Jason Rando  
(212) 827-0020  
[jrando@tiberend.com](mailto:jrando@tiberend.com)